Community/Retail

FDA officials are now requiring a new patient medication guide, providing educational information that every patient will be asked to read before receiving a GBCA, and they are requiring manufacturers of GBCAs to conduct human and animal studies to further assess the safety of these contrast agents.

Pharmacists should be aware of what components they need to address to comply in order to prep themselves for USP standards.

Netarsudil ophthalmic solution 0.02%, is a novel once-daily eye drop believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork, the main fluid drain of the eye.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.